Transitioning pharmacovigilance services to a single FSP partner
As drug and medical device developers contend with an array of complex financial pressures and struggle to find talent in competitive employment markets, they are increasingly turning to FSP models to outsource individual functional services.
Among the functional services widely selected for FSP outsourcing is pharmacovigilance (PV), which is key to every drug or medical device developer’s ability to ensure excellence in patient safety.
This white paper demonstrates the value of consolidating PV capabilities to a single FSP partner and the ways an FSP partner can overcome associated challenges, including:
- Reducing current and future financial pressures
- Mitigating problems related to breakdowns in communications and/or lack of efficiency
- Delivering global and local PV solutions
- Streamlining operations to provide a more trustworthy, comprehensive view of the entire product portfolio and its regulatory needs
